• Heather M Ochs-Balcom, Ly Minh Nguyen, Changxing Ma, Paul J Isackson, Jasmine A Luzum, Joseph P Kitzmiller, Mark Tarnopolsky, Michael Weisman, Lisa Christopher-Stine, Wendy Peltier, Robert L Wortmann, and Georgirene D Vladutiu.
• Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, 270 Farber Hall, Buffalo, New York, 14214-8001, USA.
• Muscle Nerve. 2019 May 1; 59 (5): 537-543.

IntroductionStatins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5% of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS).MethodsClinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations.ResultsIndividuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95% confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95% CI 1.18, 8.05), hypertension (OR 2.24, 95% CI 1.33, 3.77), smoking (OR 2.08, 95% CI 1.16, 3.74), and statin type.DiscussionCareful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve 59:537-537, 2019.© 2018 Wiley Periodicals, Inc.

45 keywords...

hide…